Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Express Scripts
Johnson and Johnson
McKesson
Colorcon

Last Updated: May 28, 2022

ANORO ELLIPTA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

When do Anoro Ellipta patents expire, and what generic alternatives are available?

Anoro Ellipta is a drug marketed by Glaxosmithkline and is included in one NDA. There are fifteen patents protecting this drug.

This drug has three hundred and forty patent family members in forty-seven countries.

The generic ingredient in ANORO ELLIPTA is umeclidinium bromide; vilanterol trifenatate. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the umeclidinium bromide; vilanterol trifenatate profile page.

DrugPatentWatch® Generic Entry Outlook for Anoro Ellipta

Anoro Ellipta was eligible for patent challenges on May 10, 2017.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 29, 2030. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Sign up for a Free Trial

Summary for ANORO ELLIPTA
International Patents:340
US Patents:15
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 1
Clinical Trials: 45
Patent Applications: 202
Drug Prices: Drug price information for ANORO ELLIPTA
What excipients (inactive ingredients) are in ANORO ELLIPTA?ANORO ELLIPTA excipients list
DailyMed Link:ANORO ELLIPTA at DailyMed
Drug patent expirations by year for ANORO ELLIPTA
Drug Prices for ANORO ELLIPTA

See drug prices for ANORO ELLIPTA

DrugPatentWatch® Estimated Generic Entry Opportunity Date for ANORO ELLIPTA
Generic Entry Date for ANORO ELLIPTA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
POWDER;INHALATION

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ANORO ELLIPTA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Baylor Research InstitutePhase 4
Chiesi Farmaceutici S.p.A.Phase 4
Luis Puente MaestuPhase 4

See all ANORO ELLIPTA clinical trials

US Patents and Regulatory Information for ANORO ELLIPTA

ANORO ELLIPTA is protected by fifteen US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of ANORO ELLIPTA is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting ANORO ELLIPTA

Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

Phenethanolamine derivatives for treatment of respiratory diseases
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA.

Muscarinic acetylcholine receptor antagonists
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Muscarinic acetylcholine receptor antagonists
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Counter for use with a medicament dispenser
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Medicament dispenser
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Muscarinic acetylcholine receptor antagonists
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA.

Muscarinic acetylcholine receptor antagonists
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA.

Medicament dispenser
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA.

Manifold for use in medicament dispenser
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Medicament dispenser
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Medicament dispenser
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Phenethanolamine derivatives for treatment of respiratory diseases
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA.

FDA Regulatory Exclusivity protecting ANORO ELLIPTA

ADDITIONAL INFORMATION ADDED TO THE LABELING BASED ON SAFETY AND EFFICACY DATA FROM THE IMPACT TRIAL
Exclusivity Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline ANORO ELLIPTA umeclidinium bromide; vilanterol trifenatate POWDER;INHALATION 203975-001 Dec 18, 2013 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Glaxosmithkline ANORO ELLIPTA umeclidinium bromide; vilanterol trifenatate POWDER;INHALATION 203975-001 Dec 18, 2013 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Glaxosmithkline ANORO ELLIPTA umeclidinium bromide; vilanterol trifenatate POWDER;INHALATION 203975-001 Dec 18, 2013 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for ANORO ELLIPTA

When does loss-of-exclusivity occur for ANORO ELLIPTA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 10326798
Estimated Expiration: See Plans and Pricing

Patent: 14204459
Estimated Expiration: See Plans and Pricing

Patent: 16262698
Estimated Expiration: See Plans and Pricing

Patent: 18282427
Estimated Expiration: See Plans and Pricing

Patent: 21204302
Estimated Expiration: See Plans and Pricing

Brazil

Patent: 2012012925
Estimated Expiration: See Plans and Pricing

Canada

Patent: 81487
Estimated Expiration: See Plans and Pricing

Chile

Patent: 12001432
Estimated Expiration: See Plans and Pricing

China

Patent: 2724974
Estimated Expiration: See Plans and Pricing

Patent: 7412229
Estimated Expiration: See Plans and Pricing

Colombia

Patent: 41613
Estimated Expiration: See Plans and Pricing

Costa Rica

Patent: 120265
Estimated Expiration: See Plans and Pricing

Croatia

Patent: 0180312
Estimated Expiration: See Plans and Pricing

Cyprus

Patent: 20058
Estimated Expiration: See Plans and Pricing

Denmark

Patent: 06844
Estimated Expiration: See Plans and Pricing

Dominican Republic

Patent: 012000148
Estimated Expiration: See Plans and Pricing

Eurasian Patent Organization

Patent: 3839
Estimated Expiration: See Plans and Pricing

Patent: 1290266
Estimated Expiration: See Plans and Pricing

European Patent Office

Patent: 06844
Estimated Expiration: See Plans and Pricing

Patent: 35707
Estimated Expiration: See Plans and Pricing

Hong Kong

Patent: 49407
Estimated Expiration: See Plans and Pricing

Hungary

Patent: 36216
Estimated Expiration: See Plans and Pricing

Patent: 800027
Estimated Expiration: See Plans and Pricing

Israel

Patent: 9893
Estimated Expiration: See Plans and Pricing

Japan

Patent: 16631
Estimated Expiration: See Plans and Pricing

Patent: 13512270
Estimated Expiration: See Plans and Pricing

Lithuania

Patent: 2018011
Estimated Expiration: See Plans and Pricing

Patent: 06844
Estimated Expiration: See Plans and Pricing

Luxembourg

Patent: 0077
Estimated Expiration: See Plans and Pricing

Mexico

Patent: 1290
Estimated Expiration: See Plans and Pricing

Patent: 12006310
Estimated Expiration: See Plans and Pricing

Montenegro

Patent: 965
Estimated Expiration: See Plans and Pricing

Morocco

Patent: 853
Estimated Expiration: See Plans and Pricing

New Zealand

Patent: 0026
Estimated Expiration: See Plans and Pricing

Norway

Patent: 06844
Estimated Expiration: See Plans and Pricing

Peru

Patent: 130042
Estimated Expiration: See Plans and Pricing

Patent: 170915
Estimated Expiration: See Plans and Pricing

Poland

Patent: 06844
Estimated Expiration: See Plans and Pricing

Portugal

Patent: 06844
Estimated Expiration: See Plans and Pricing

Serbia

Patent: 848
Estimated Expiration: See Plans and Pricing

Singapore

Patent: 1087
Estimated Expiration: See Plans and Pricing

Patent: 201407864U
Estimated Expiration: See Plans and Pricing

Slovenia

Patent: 06844
Estimated Expiration: See Plans and Pricing

South Africa

Patent: 1203890
Estimated Expiration: See Plans and Pricing

South Korea

Patent: 1742140
Estimated Expiration: See Plans and Pricing

Patent: 1830728
Estimated Expiration: See Plans and Pricing

Patent: 120092163
Estimated Expiration: See Plans and Pricing

Patent: 170061719
Estimated Expiration: See Plans and Pricing

Spain

Patent: 59330
Estimated Expiration: See Plans and Pricing

Turkey

Patent: 1802921
Estimated Expiration: See Plans and Pricing

Ukraine

Patent: 6775
Estimated Expiration: See Plans and Pricing

United Kingdom

Patent: 21075
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ANORO ELLIPTA around the world.

Country Patent Number Title Estimated Expiration
Czech Republic 9601807 See Plans and Pricing
South Korea 100912324 See Plans and Pricing
Singapore 150525 COUNTER FOR USE WITH A MEDICAMENT DISPENSER See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ANORO ELLIPTA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1425001 PA2014019 Lithuania See Plans and Pricing PRODUCT NAME: VILANTEROLUM; REGISTRATION NO/DATE: EU/1/13/886/001-006 20131113
1425001 14C0028 France See Plans and Pricing PRODUCT NAME: VILANTEROL OU UN SEL OU UN SOLVATE DE CELUI-CI,EN PARTICULIER LE TRIFENATATE DE VILANTEROL.; REGISTRATION NO/DATE: EU/1/13/886/001-006 20131113
2506844 18C1022 France See Plans and Pricing PRODUCT NAME: COMBINAISON COMPRENANT UN SEL PHARMACEUTIQUEMENT ACCEPTABLE D'UMECLIDINIUM (EN PARTICULIER LE BROMURE D'UMECLIDINIUM), DU VILANTEROL OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI (EN PARTICULIER LE TRIFENATATE DE VILANTEROL), ET DU FUROATE DE FLUTICASONE; REGISTRATION NO/DATE: EU/1/17/1236 20171117
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Baxter
Medtronic
Boehringer Ingelheim
Johnson and Johnson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.